This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
by Zacks Equity Research
LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.
Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company
by Zacks Equity Research
Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company
3 Best Stocks with Upgraded Broker Ratings to Invest In Now
by Zacks Equity Research
Selecting stocks from the vast investment universe is not an easy task. In such a situation, sound broker advice helps to pick the right stocks.
Haemonetics Banks on Solid Plasma & Haemonetics Management
by Zacks Equity Research
Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).
Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.
Why Earnings Season Could Be Great for Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Can PerkinElmer (PKI) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat outlook, volatility in the foreign exchange rate is likely to mar PerkinElmer's (PKI) results in the second quarter.
Haemonetics Plasma Arm Advances, Blood Center Sluggish
by Zacks Equity Research
On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).
Haemonetics Rides on Solid Plasma, Slows Blood Center Growth
by Zacks Equity Research
On Jun 13, we issued an updated research report on Haemonetics Corporation (HAE).
Haemonetics (HAE) Down 2.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.
Haemonetics' Plasma Group Strong, Blood Center Group a Drag
by Zacks Equity Research
On Apr 11, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE), a leading provider of blood management solutions.
Why Is Haemonetics (HAE) Up 3.5% Since the Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.
Medical Product Stocks' Earnings on Feb 6: HAE, PAHC & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their quarterly reports on Feb 6.
Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.10 in first-quarter fiscal 2017, up 6.8% from the year-ago quarter.
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the buyout of Hennigsdorf, Germany-based InVivo Biotech Services GmbH.
Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the acquisition of Bremen, Germany-based software solutions developer, SCiLS GmbH.
ResMed Achieves Key Milestone in Sleep-Disordered Breathing
by Zacks Equity Research
After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.
Illumina Fettered With Losses: Can It Bounce Back in 2017?
by Zacks Equity Research
During majority of the past one year, Illumina (ILMN) lagged the Zacks classified broader Medical - Biomedical and Genetics industry.
Masimo to Launch Advanced Monitoring Technologies in India
by Zacks Equity Research
Masimo (MASI) announced that it will launch Advanced Monitoring Technologies in the Indian market.
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3
by Zacks Equity Research
OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.
Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold?
by Zacks Equity Research
On Jan 2, 2017, Abaxis Inc. (ABAX), a leading manufacturer of portable medical and veterinary blood analysis systems, was upgraded to a Zacks Rank #3 (Hold).